VERAXA Biotech (@VERAXABiotech) header
VERAXA Biotech (@VERAXABiotech) profile picture

At VERAXA Biotech (NASDAQ: VRXA) we are focused on pioneering antibody innovations to defeat cancer through next-generation antibody-based therapeutics.

Zurich, Switzerland
Joined March 2026
Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)Photo by VERAXA Biotech (@VERAXABiotech)
VERAXA Biotech presents at #PEGSEurope 2026 in Lisbon, 16-19 Nov. Four sessions on superior tumor selectivity: BiTAC-TCE (VXA-102 talk, Tue 17 Nov 9:00 WET; poster A111) and a bispecific ADC (VXA-221 talk, Wed 18 Nov 19:00 WET; poster B117). Book a meeting. #BiTAC #ADCs
11
🎯 New publication on fast click chemistry for #ADC development highlights $VRXA's chemistry expertise. Producing a safe and effective ADC requires attaching a potent cancer drug to an antibody with high precision. Find the open access paper at: tinyurl.com/2z4bp4aj
1
33
Heading to the 17th World ADC San Diego Summit, Oct 12-15! $VERAXA’s Dr. Christoph Erkel, CSO, and Dr. Paul Sauter, Senior Director ADC Tech & Chemistry, will be on-site to share how we're building on our BiTAC® platform to shape what’s next in #ADC design. Stay tuned for more!
2
25
🔬 What if preclinical cancer research could better predict patient response? $VRXA’s NAMs are ahead of the FDA’s 2025 roadmap. Read more: tinyurl.com/355vyu77 #PreclinicalResearch #NAMs #ADCs #TCEs
32
$VRXA CEO & Co-Founder, Christoph Antz, PhD, will be participating in a panel on "Developing the Next Generation of Innovations in Antibody-Drug Conjugates (ADCs)" as part of the ICR Healthcare Conference Series. Register here: icr.swoogo.com/adc/begin #ADCs #Biopharma
22
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic. For more see: bit.ly/3Tb45pK $VRXA #Biotech #ADCs #TCEs
1
115
🔬 $VRXA & Secarna Pharmaceuticals share initial positive results from their strategic research collaboration to develop next-gen AOCs. Our AOC molecules showed greater potency than naked oligonucleotides. Read more: bit.ly/4xhBX2W #Biotech #DrugDevelopment
36
Today is World Lung Cancer Day, and we at Veraxa Biotech stand with the millions of patients around the world fighting for better treatment options. #WorldLungCancerDay2026 #TogetherThroughLungCancer #LungCancerResearch
3
15
VERAXA strengthens patent portfolio with core BiTAC filings covering T cell engagers, ADCs, payloads & conjugation tech across the BiTAC-TCE and BiTAC-ADC platforms. Our dual-component architecture enhances tumor selectivity & safety. tinyurl.com/awsyk9tr #Biotech $VRXA
3
4
52
VXA-222 advances! Our bsADC program with @OmniAb has hit a key technical milestone, moving into its next phase. VXA-222 uses "AND-gate" logic to target 2 antigens on solid tumors with one molecule. Details: tinyurl.com/bdd5fztj #VERAXA #Oncology #ADCs $VRXA
42
We're thrilled to welcome Dr. Christoph Erkel as our new Chief Scientific Officer! His background and translational expertise will be key to advancing our #BiTAC® platform through clinical development. For more see: tinyurl.com/2bdb3rcx $VRXA #Biotech #ADCs #TCEs
12
13
202
🚀 $VRXA at the 4th ADC Linker & Conjugation Summit, Boston, July 28-30! On July 29, Dr. Paul Sauter will present on hydrophilic click chemistry for #ADC selectivity (9:30 a.m. ET) & join a panel on ADC toxicity strategy (12:00 p.m. ET). Register: tinyurl.com/bdhzahvt
1
57
$VRXA has received positive scientific advice from @PEI_Germany on our BiTAC-TCE technology, de-risking our path forward and building on encouraging #AACR2026 data showing a superior safety profile vs. traditional #TCEs. Read more: tinyurl.com/5n84k7uh #VERAXA #Oncology
45
$VRXA is teaming up with @Ardigen_SA to bring AI to our BiTAC® pipeline! Together, we’re optimizing cancer target pair selection for BiTAC-TCEs and future BiTAC-ADCs advancing precision #oncology designed to spare healthy tissue. Read more: bit.ly/4aPcK6U
1
2
55
🧬 $VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering. Read more: bit.ly/4eZPKU6 #Biotech #Oncology
1
5
7
234
The right partner makes all the difference. #VERAXA has selected #ATUM, a leading US/West Coast CRO, to lead cell line development for our lead BiTAC®-TCE program, a first step toward manufacturing for preclinical & clinical material. Read more: bit.ly/3RaJalE #Oncology
9
10
198
#VERAXA Biotech is expanding its R&D hub in Heidelberg, Germany! A 60%+ increase in lab space will accelerate our BiTAC-TCE and BiTAC-ADC programs toward clinical development – right at the heart of world-class medical #oncology. Read more: bit.ly/4vum6Ny #Biotech
1
10
10
272
We’re excited to share new proof‑of‑concept data for our BiTAC‑ADC technology. Together with our BiTAC‑TCE platform, we have two differentiated technologies powering our approach to solid tumors therapies. Read more: bit.ly/44irVBM #VERAXA #Biotech #Oncology
18
18
293
🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25! Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies. Schedule via BIO One-on-One!
1
63
🎉 #VERAXA Biotech begins trading today on NASDAQ ($VRXA)! As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue. bit.ly/4ooC21e
2
58